Clinical Trials on Persistent/Recurrent Minimal Residual Disease (MRD) in Netherlands

Total 5 results

Amgen

Terminated

A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

Myelodysplastic Syndrome | Relapsed/Refractory AML | Minimal Residual Disease Positive AML

United States, Canada, Germany, Netherlands
Wuerzburg University Hospital
Royal Marsden NHS Foundation Trust

Completed

Fractionated Radiosurgery for Painful Spinal Metastases (DOSIS)

Pain | Neoplasm Metastasis | Neoplastic Processes | Neoplasm, Residual | Neoplasm Recurrence, Local

Switzerland, Netherlands, Germany, United Kingdom
Institut de Recherches Internationales Servier

Active, not recruiting

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Recurrent Glioma | Grade 2 Glioma | Residual Glioma

United States, Canada, Spain, Italy, United Kingdom, Switzerland, Israel, Japan, Netherlands, Germany, France
Amgen Research (Munich) GmbH

Completed

Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) (BLAST)

B-cell Acute Lymphoblastic Leukemia

Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Romania, Russian Federation, Spain, United Kingdom
Abbott Medical Devices

Completed

High-Density (HD) Wave Mapping in Subjects With Atrial Fibrillation as a Predictor of Recurrence After a Single Ablation Procedure Using a PVI-Only Strategy (WAVE-MAP AF)

Cardiac Arrhythmia | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation

Spain, United Kingdom, Germany, Italy, Austria, Czechia, France, Netherlands, Portugal

Clinical Trials on Persistent/Recurrent Minimal Residual Disease (MRD) in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations